Clinical Trials Browser

Paroxysmal nonkinesigenic dyskinesia, Leukemia, Neoplasm Metastasis, Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04024761 2026-04-03

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Phase 1 Recruiting

50 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Juvenile

NCT05544968 2026-04-03

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Phase 1 Recruiting

42 enrolled

LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Neoplasms, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT06313437 2026-03-25

Revumenib in Combination With 7+3 + Midostaurin in AML

Phase 1 Recruiting

22 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT04629729 2026-03-19

FT819 in Subjects With B-cell Malignancies

Phase 1 Active not recruiting

54 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

NCT06152809 2026-03-18

CIML NK Cells With Venetoclax for AML

Phase 1 Recruiting

10 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Phase 1 Recruiting

420 enrolled

Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

NCT07464951 2026-03-11

CART123

Phase 1 Not yet recruiting

30 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT07044544 2026-03-04

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Phase 1 Recruiting

20 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07439211 2026-03-03

GAVEL

Phase 1 Not yet recruiting

48 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT03974217 2026-02-25

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Phase 1 Active not recruiting

13 enrolled

Other hematologic neoplasm

Leukemia

NCT05170828 2026-02-24

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Phase 1 Withdrawn

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06522373 2026-02-24

Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease

Phase 1 Withdrawn

Other hematologic neoplasm

Leukemia

NCT03826992 2026-02-18

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Phase 1 Recruiting

21 enrolled

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT07392814 2026-02-17

TOCIVENA

Phase 1 Not yet recruiting

12 enrolled

Other hematologic neoplasm

Leukemia

NCT06408194 2026-02-10

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Phase 1 Recruiting

20 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06810583 2026-02-03

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

Phase 1 Recruiting

29 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT05787496 2026-01-28

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Phase 1 Terminated

28 enrolled 19 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Clinical Trials

Study of Tazemetostat in Lymphoid Malignancies

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.

ThINKK-01

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Revumenib in Combination With 7+3 + Midostaurin in AML

FT819 in Subjects With B-cell Malignancies

CIML NK Cells With Venetoclax for AML

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

CART123

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

GAVEL

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

TOCIVENA

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms